Bleeding and thrombosis in hematologic neoplasia

Joseph J. Shatzel, Robyn Scherber, Thomas Deloughery

    Research output: Chapter in Book/Report/Conference proceedingChapter

    Abstract

    Excessive bleeding or thrombosis complicates the treatment of many patients with hematologic malignancies. The pathogenesis and therapy of some of these disorders, such as thrombocytopenia due to invasion of the marrow by tumor cells or chemotherapy, is usually straightforward. However, other hemostatic defects are more complex. For example: 1. Malignant cells can produce and release thromboplastic or fibrinolytic substances that cause disseminated intravascular coagulation (DIC) or primary fibrinolysis (for example, acute promyelocytic leukemia) (APL). 2. The pathologic process can provoke the megakaryocyte to produce dysfunctional platelets with bleeding or thrombosis (chronic myeloproliferative disorders). 3. Abnormal lymphocytes or plasma cells sometimes produce aberrant proteins that interfere with normal hemostasis (multiple myeloma, amyloid). 4. Certain antitumor or antimicrobial agents used in the treatment of malignancy or its complications can cause thrombosis or bleeding (1-asparaginase or some β-lactam antibiotics). This chapter focuses on bleeding and thrombotic disorders that are associated with hematologic neoplasia. Thrombocytopenic bleeding and of platelet transfusion therapy is covered elsewhere in this volume.

    Original languageEnglish (US)
    Title of host publicationNeoplastic Diseases of the Blood
    PublisherSpringer International Publishing
    Pages1263-1289
    Number of pages27
    ISBN (Electronic)9783319642635
    ISBN (Print)9783319642628
    DOIs
    StatePublished - Jan 1 2018

    Fingerprint

    Thrombosis
    Hemorrhage
    Neoplasms
    Asparaginase
    Lactams
    Myeloproliferative Disorders
    Platelet Transfusion
    Acute Promyelocytic Leukemia
    Megakaryocytes
    Disseminated Intravascular Coagulation
    Fibrinolysis
    Hemostatics
    Hematologic Neoplasms
    Pathologic Processes
    Therapeutics
    Anti-Infective Agents
    Plasma Cells
    Hemostasis
    Multiple Myeloma
    Amyloid

    Keywords

    • Disseminated intravascular coagulation
    • Eculizumab
    • Leukemia
    • Myeloma
    • PNH
    • Veno occlusive disease

    ASJC Scopus subject areas

    • Medicine(all)

    Cite this

    Shatzel, J. J., Scherber, R., & Deloughery, T. (2018). Bleeding and thrombosis in hematologic neoplasia. In Neoplastic Diseases of the Blood (pp. 1263-1289). Springer International Publishing. https://doi.org/10.1007/978-3-319-64263-5_59

    Bleeding and thrombosis in hematologic neoplasia. / Shatzel, Joseph J.; Scherber, Robyn; Deloughery, Thomas.

    Neoplastic Diseases of the Blood. Springer International Publishing, 2018. p. 1263-1289.

    Research output: Chapter in Book/Report/Conference proceedingChapter

    Shatzel, JJ, Scherber, R & Deloughery, T 2018, Bleeding and thrombosis in hematologic neoplasia. in Neoplastic Diseases of the Blood. Springer International Publishing, pp. 1263-1289. https://doi.org/10.1007/978-3-319-64263-5_59
    Shatzel JJ, Scherber R, Deloughery T. Bleeding and thrombosis in hematologic neoplasia. In Neoplastic Diseases of the Blood. Springer International Publishing. 2018. p. 1263-1289 https://doi.org/10.1007/978-3-319-64263-5_59
    Shatzel, Joseph J. ; Scherber, Robyn ; Deloughery, Thomas. / Bleeding and thrombosis in hematologic neoplasia. Neoplastic Diseases of the Blood. Springer International Publishing, 2018. pp. 1263-1289
    @inbook{4a66785c257f4d2fb50f66b316f74e40,
    title = "Bleeding and thrombosis in hematologic neoplasia",
    abstract = "Excessive bleeding or thrombosis complicates the treatment of many patients with hematologic malignancies. The pathogenesis and therapy of some of these disorders, such as thrombocytopenia due to invasion of the marrow by tumor cells or chemotherapy, is usually straightforward. However, other hemostatic defects are more complex. For example: 1. Malignant cells can produce and release thromboplastic or fibrinolytic substances that cause disseminated intravascular coagulation (DIC) or primary fibrinolysis (for example, acute promyelocytic leukemia) (APL). 2. The pathologic process can provoke the megakaryocyte to produce dysfunctional platelets with bleeding or thrombosis (chronic myeloproliferative disorders). 3. Abnormal lymphocytes or plasma cells sometimes produce aberrant proteins that interfere with normal hemostasis (multiple myeloma, amyloid). 4. Certain antitumor or antimicrobial agents used in the treatment of malignancy or its complications can cause thrombosis or bleeding (1-asparaginase or some β-lactam antibiotics). This chapter focuses on bleeding and thrombotic disorders that are associated with hematologic neoplasia. Thrombocytopenic bleeding and of platelet transfusion therapy is covered elsewhere in this volume.",
    keywords = "Disseminated intravascular coagulation, Eculizumab, Leukemia, Myeloma, PNH, Veno occlusive disease",
    author = "Shatzel, {Joseph J.} and Robyn Scherber and Thomas Deloughery",
    year = "2018",
    month = "1",
    day = "1",
    doi = "10.1007/978-3-319-64263-5_59",
    language = "English (US)",
    isbn = "9783319642628",
    pages = "1263--1289",
    booktitle = "Neoplastic Diseases of the Blood",
    publisher = "Springer International Publishing",

    }

    TY - CHAP

    T1 - Bleeding and thrombosis in hematologic neoplasia

    AU - Shatzel, Joseph J.

    AU - Scherber, Robyn

    AU - Deloughery, Thomas

    PY - 2018/1/1

    Y1 - 2018/1/1

    N2 - Excessive bleeding or thrombosis complicates the treatment of many patients with hematologic malignancies. The pathogenesis and therapy of some of these disorders, such as thrombocytopenia due to invasion of the marrow by tumor cells or chemotherapy, is usually straightforward. However, other hemostatic defects are more complex. For example: 1. Malignant cells can produce and release thromboplastic or fibrinolytic substances that cause disseminated intravascular coagulation (DIC) or primary fibrinolysis (for example, acute promyelocytic leukemia) (APL). 2. The pathologic process can provoke the megakaryocyte to produce dysfunctional platelets with bleeding or thrombosis (chronic myeloproliferative disorders). 3. Abnormal lymphocytes or plasma cells sometimes produce aberrant proteins that interfere with normal hemostasis (multiple myeloma, amyloid). 4. Certain antitumor or antimicrobial agents used in the treatment of malignancy or its complications can cause thrombosis or bleeding (1-asparaginase or some β-lactam antibiotics). This chapter focuses on bleeding and thrombotic disorders that are associated with hematologic neoplasia. Thrombocytopenic bleeding and of platelet transfusion therapy is covered elsewhere in this volume.

    AB - Excessive bleeding or thrombosis complicates the treatment of many patients with hematologic malignancies. The pathogenesis and therapy of some of these disorders, such as thrombocytopenia due to invasion of the marrow by tumor cells or chemotherapy, is usually straightforward. However, other hemostatic defects are more complex. For example: 1. Malignant cells can produce and release thromboplastic or fibrinolytic substances that cause disseminated intravascular coagulation (DIC) or primary fibrinolysis (for example, acute promyelocytic leukemia) (APL). 2. The pathologic process can provoke the megakaryocyte to produce dysfunctional platelets with bleeding or thrombosis (chronic myeloproliferative disorders). 3. Abnormal lymphocytes or plasma cells sometimes produce aberrant proteins that interfere with normal hemostasis (multiple myeloma, amyloid). 4. Certain antitumor or antimicrobial agents used in the treatment of malignancy or its complications can cause thrombosis or bleeding (1-asparaginase or some β-lactam antibiotics). This chapter focuses on bleeding and thrombotic disorders that are associated with hematologic neoplasia. Thrombocytopenic bleeding and of platelet transfusion therapy is covered elsewhere in this volume.

    KW - Disseminated intravascular coagulation

    KW - Eculizumab

    KW - Leukemia

    KW - Myeloma

    KW - PNH

    KW - Veno occlusive disease

    UR - http://www.scopus.com/inward/record.url?scp=85047051027&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85047051027&partnerID=8YFLogxK

    U2 - 10.1007/978-3-319-64263-5_59

    DO - 10.1007/978-3-319-64263-5_59

    M3 - Chapter

    AN - SCOPUS:85047051027

    SN - 9783319642628

    SP - 1263

    EP - 1289

    BT - Neoplastic Diseases of the Blood

    PB - Springer International Publishing

    ER -